Lung tumors: early and delayed ratio of 99mTc-methoxy-2-isobutylisonitrile accumulation
Abstract
Background/Aim. Currently used radiopharmaceuticals are nonspecific and most of them are accumulated by benign tumors as well as inflammatory lesions, abscess or granulomatous lesions. Some factors such as the choice of radiopharmaceutical applied, histopathologic type of tumor, its size, location or previous tumor treatment could influence tumor imaging sensitivity. The aim of this study was to investigate accumulation of 99mTc-methoxy-2-isobutylisonitrile (99mTc-MIBI) by counting early/delayed uptake and release of this radiopharmaceutical inside lung tumors and evaluating possible factors which could be involved in its accumulation. Methods. Two-phase 99mTc-methoxy-2-isobutylisonitrile single photon emission computed tomography scan (early and delayed scan) was performed in 60 patients with lung tumors (the group 1 – 30 benign, and the group 2 – 30 malignant tumors). We calculated the uptake ratio on early (early ratio – ER), delayed images (delayed ratio – DR) and retention index (RI). Individual influence of etiology, diameter, localization, and histological type on uptake/release values was evaluated with regression analysis. Results. The values of ER and DR were significantly different in both groups (p < 0.01), showing lower values in benign vs malignant lung tumors (ER 1.36 ± 0.094 and DR 1.25 ± 0.089 vs ER = 1.93 ± 0.106 and DR = 1.7 ± 0.095 respectively). Tumor size showed a significant influence on the change of ER and DR values (p < 0.01), with greater uptake in tumors > 3 cm. RI values showed no significance between the two groups (p > 0.05). Conclusion. The uptake ratio of 99mTc-methoxy-2-isobutylisonitrile could be a useful index in differentiating lung tumors, while RI has no influence on this. Among the evaluated factors, ER and DR values are significantly influenced only by the diameter of lung tumor, while localization or different histological types between the groups has no influence on this.
References
Yamamoto Y, Nishiyama Y, Fukunaga K, Kobayashi T, Satoh K, Fujita J, et al. Evaluation of histopathological differentiation in lung adenocarcinoma patients using 201Tl-chloride and 99Tcm-MIBI SPET. Nucl Med Commun 2001; 22(5): 539−45.
Kashitani N, Makihara S, Maeda T, Eda R, Takeyama H, Hiraki Y. Thallium-201-chloride and technetium-99m-MIBI SPECT of primary and metastatic lung carcinoma. Oncol Rep 1999; 6(1): 127−33.
Yamamoto Y, Kawasaki Y, Nishiyama Y, Fukunaga K, Satoh K, Takashima H, et al. Comparative evaluation of 99mTc-MIBI (hexakis2-methoxy isobutyl isonitrile) and 201Tl-chloride in primary lung cancer. Kaku Igaku 1996; 33(5): 501−11.
Kanaev SV, Novikov SN, Beĭnusov DS, Girtovich MM, Levchenko EV, Barchuk AS, et al. Use of simultaneous double-tracer SPECT with 99m-Tc-technetril and 67-Ga-citrate for follow-up of patients with non-small cell lung cancer. Vopr Onkol 2012; 58(3): 346−51.
Komori T, Matsui R, Adachi I, Shimizu T, Sueyoshi K, Narabayashi I. In vitro uptake and release of 201Tl and 99mTc-MIBI in HeLa cell. Kaku Igaku 1995; 32(7): 651−8.
Matsui R, Komori T, Namba R, Shimizu T, Sueyoshi K, Sano K, et al. In vitro uptake and release of TI-201 and Tc-99m MIBI in cultured tumor cells and effect of anticancer drug. Radiat Med 1998; 16(3): 187−94.
Sergieva S, Hadjieva T, Doldurova M, Stefanova S, Dudov A. Nuclear medicine approaches in the monitoring of thyroid cancer patients. J BUON 2006; 11(4): 511−8.
Nagai H, Yamasaki T, Yamamoto Y, Takada D, Miyazaki T, Su-gimoto K, et al. Evaluation of brain tumors by simultaneous dual isotope SPECT with 201Tl-chloride and 99mTc-MIBI. No Shinkei Geka 2004; 32(10): 1029−37.
Yildiz A, Garipağaoğlu M, Güngör F, Boz A, Dalmaz G. The role of technetium-99m methoxyisobutyl isonitrile scintigraphy in suspected recurrent breast cancer. Cancer Biother Radiopharm 2001; 16(2): 163−9.
Nikoletic K, Lucic S, Peter A, Kolarov V, Zeravica R, Srbovan D. Lung 99mTc-MIBI scintigraphy: impact on diagnosis of soli-tary pulmonary nodule. Bosn J Basic Med Sci 2011; 11(3): 174−9.
Minai OA, Raja S, Mehta AC, Sullivan EJ, Khan SU, Dasgupta A, et al. Role of Tc-99m MIBI in the evaluation of single pulmo-nary nodules: a preliminary report. Thorax 2000; 55(1): 60−2.
Komori T, Narabayashi I, Matsui R, Sueyoshi K, Aratani T, Utsuno-miya K. Technetium-99m MIBI single photon emission com-puted tomography as an indicator of prognosis for patients with lung cancer-preliminaly report. Ann Nucl Med 2000; 14(6): 415−20.
Hassan IM, Sahweil A, Constantinides C, Mahmoud A, Nair M, Omar YT, et al. Uptake and kinetics of Tc-99m hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs. Clin Nucl Med 1989; 14(5): 333−40.
Shirakawa T, Mori Y, Moriya E, Dohi M, Kawakami K, Akiba T, et al. Uptake of Tc-99m hexakis 2-methoxy isobutyl isonitrile in lung or mediastinal lesions by SPECT. Nihon Igaku Hoshasen Gakkai Zasshi 1995; 55(8): 587−92. (Japanese)
Komori T, Narabayashi I, Matsui R, Tatsu Y, Sueyoshi K, Adachi I, et al. Evaluation of uptake and release of technetium-99m MIBI SPECT of pulmonary and mediastinal lesions. Ann Nucl Med 1997; 11(3): 227−32.
Chiu ML, Herman LW, Kronauge JF, Piwnica-Worms D. Compara-tive effects of neutral dipolar compounds and lipophilic anions on technetium 99m-hexakis (2-methoxyisobutyl isonitrile) accumulation in cultured chick ventricular myocytes. Invest Radiol 1992; 27(12): 1052−8.
Del Vecchio S, Ciarmiello A, Salvatore M. Scintigraphic detection of multidrug resistance in cancer. Cancer Biother Radiopharm 2000; 15(4): 327−37.
Mohan HK, Miles KA. Cost-effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis. J Nucl Med 2009; 50(3): 376−81.
Scopinaro F, De VG, Pani R, Pellegrini R, Banci M, Casu C, et al. 99Tcm-MIBI uptake in green plants. Nucl Med Commun 1994; 15(11): 905−15.
Nishiyama Y, Kawasaki Y, Yamamoto Y, Fukunaga K, Satoh K, Takashima H, et al. Technetium-99m-MIBI and thallium-201 scintigraphy of primary lung cancer. J Nucl Med 1997; 38(9): 1358−61.
Yamamoto Y, Nishiyama Y, Fukuda Y, Satoh K, Ohkawa M, Tanabe M. Differentiation of small solitary pulmonary nodules using Tc-99m MIBI and Tl-201 SPECT. Clin Nucl Med 1999; 24(10): 751−5.
Santini M, Fiorello A, Mansi L, Rambaldi PF, Vicidomini G, Busiello L, et al. The role of technetium-99m hexakis-2-methoxyisobutyl isonitrile in the detection of neoplastic lung lesions. Eur J Cardiothorac Surg 2009; 35(2): 325−31.
Nosotti M, Santambrogio L, Gasparini M, Baisi A, Bellaviti N, Rosso L. Role of (99m)tc-hexakis-2-methoxy-isobutylisonitrile in the diagnosis and staging of lung cancer. Chest 2002; 122(4): 1361−4.
Oskoei SD, Mahmoudian B. A comparative study of lung masses with 99mTechnetium Sestamibi and pathology results. Pak J Biol Sci 2007; 10(2): 225−9.
Robbins SL, Kumar V. Basic pathology. Philadelphia: W.B. Saunders; 1987.
Onsel C, Sönmezoglu K, Camsari G, Atay S, Cetin S, Erdil YT, et al. Technetium-99m-MIBI scintigraphy in pulmonary tubercu-losis. J Nucl Med 1996; 37(2): 233−8.
Chun EJ, Lee HJ, Kang WJ, Kim KG, Goo JM, Park CM, et al. Differentiation between malignancy and inflammation in pul-monary ground-glass nodules: The feasibility of integrated (18)F-FDG PET/CT. Lung Cancer 2009; 65(2): 180−6.
Sahin M, Ozcan A, Bernay I, Basoglu T, Demircali T, Uzun O, et al. Radioisotopic Evaluation of Malignant Lung Tumors: A Technetium-99m-Methoxy-Isobutilisonitrile Study. Tr J Med Sci 1999; 29: 135−40.
